Chemveda Life Sciences

Founded in 2008 by Dr. Bheema Rao Paraselli, Chemveda Life Sciences has grown into a global CRDMO (Contract Research, Development, and Manufacturing Organization) with a strong focus on synthetic chemistry. The company leverages a team of over 450 scientists and 600 total employees to offer end-to-end services, from gram-scale synthesis to multi-kilogram GMP manufacturing, across diverse chemistry classes including small molecules, peptides, and oligonucleotide conjugates. Guided by a distinguished scientific advisory board and leadership with deep industry experience, Chemveda is positioned as an innovation-driven market challenger, helping clients reduce time to market while ensuring robust IP protection and a 'Zero Harm' safety culture.

A comprehensive CRDMO platform specializing in complex synthetic chemistry, offering integrated services from discovery and process R&D to GMP manufacturing for small molecules, peptides, oligonucleotide conjugates (GalNAc), and other novel modalities.

Chemveda competes with large global CDMOs (e.g., Lonza, Catalent), India-based peers (e.g., Syngene, Aragen), and specialized chemistry CROs. Its differentiation lies in its focus on solving complex chemistry challenges, a 'Zero-Conflict' pure-service model, a prestigious scientific advisory board, and an integrated service offering from discovery to commercial manufacturing.